HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Task Force Created To Promote Transparency, Solicit Public Input

This article was originally published in The Rose Sheet

Executive Summary

FDA's formation of an internal Transparency Task Force is a savvy move that allows agency leaders to begin making good on their pledge to enhance openness while having six months before them to decide how exactly that will be done

You may also be interested in...



Transparency Initiative In "What Is The Right Thing To Do" Phase - Sharfstein

In June, FDA launched an internal Transparency Task Force to evaluate how to make the agency's decision-making process clearer to the public (1"The Rose Sheet" June 15, 2009). The task force held two public meetings and accepted comments through Nov. 6. FDA Principal Deputy Commissioner Joshua Sharfstein, who chairs the task force, spoke to Elsevier Business Intelligence's "The Pink Sheet" about its initial findings, with draft recommendations expected by January.

Transparency Initiative In "What Is The Right Thing To Do" Phase - Sharfstein

In June, FDA launched an internal Transparency Task Force to evaluate how to make the agency's decision-making process clearer to the public (1"The Rose Sheet" June 15, 2009). The task force held two public meetings and accepted comments through Nov. 6. FDA Principal Deputy Commissioner Joshua Sharfstein, who chairs the task force, spoke to Elsevier Business Intelligence's "The Pink Sheet" about its initial findings, with draft recommendations expected by January.

FDA transparency comments through Nov. 6

FDA will accept comments on its transparency initiative through Nov. 6, after which time the Transparency Task Force will conduct its second public meeting. The agency posts initiative information on its transparency Web site, which will operate while the comment docket is open. The task force consists of Principal Deputy Commissioner Josh Sharfstein, the directors of each of FDA's centers, acting Associate Commissioner for Regulatory Affairs Michael Chappell, acting Chief Counsel Michael Landa and acting Chief Scientist Jesse Goodman. Attorney Afia Asamoah, special assistant to Sharfstein, helps staff the task force, and policy analyst Erik Mettler oversees the blog. Commissioner Margaret Hamburg appointed the task force to identify how to improve communication and better explain agency decisions (1"The Rose Sheet" June 15, 2009)

Related Content

UsernamePublicRestriction

Register

RS016214

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel